Novelion Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017; Reiterates Revenue Guidance for the Full Year 2017
For the nine months, the company reported net revenues of USD 99,530,000. Loss from operations was USD 72,834,000 compared to USD 22,346,000 a year ago. Loss before provision for income taxes was USD 101,380,000 compared to USD 33,054,000 a year ago. Net loss was USD 102,142,000 compared to USD 32,950,000 a year ago. Basic and diluted net loss per common share was USD 5.49 compared to USD 3.12 a year ago. Non-GAAP net loss was USD 26,699,000 compared to USD 111,719,000 a year ago. Non-GAAP net loss per common share - basic was USD 1.44 compared to USD 10.57 a year ago.
The company reiterated its previously stated net revenues financial guidance for full year 2017 and expects: total net revenues between USD 135 million and USD 145 million; JUXTAPID net revenues between USD 70 million and USD 75 million; and MYALEPT net revenues between USD 65 million and USD 70 million.